US FDA Sought Patient Viewpoint On Hemlibra's Benefit/Risk Profile

Hemophilia patient advocate expressed concerns to FDA about ability of hemophilia treatment centers to educate patients about thrombotic microangiopathy and thromboembolic events, unexpected but serious cases of which were seen in the clinical program.